Summary of the technology
"Slow release L-DOPA analogs LDA and NALDA, for the treatment of Parkinson’s disease and other related indications. LDA and NALDA are highly lipophyllic and penetrate the brain very efficiently crossing the cell membrane. This property increases the bioavailability of L-DOPA in the brain, and allows smaller amounts to be used compared to that of L-DOPA. The new carriers become substrates for the aromatic amino acid decarboxylase (AADC) only in vivo. This property could eliminate the use of AADC inhibitor (carbidopa) from the treatment of PD patients. The slow conversion of these carriers in the brain to L-DOPA represents a slow release mode of drug administration. A gradual formation of L-DOPA,
would mimic the advantages of a constant and gradual level of dopamine, typical of slow drug medication."
Project ID : 7-2006-138
Description of the technology
Novel treatment for Parkinson’s disease overcomes “on-off” phenomenon
Parkinson’s disease, L-dopa, L-dopa amide
Concept proven, in vivo human models
Pending patent application in, Europe, US and Israel (PCT publication № WO2004/069146)
Increases the endogenous level of dopamine to alleviate the motor complications of Parkinson’s disease and to delay the onset of the symptoms from the dramatic decrease in dopamine
Formulated for buccal, oral, sub-lingual, parenteral, intranasal, intramuscular, intravenous, subcutaneous, intraduodenal or rectal administration
Provides a pharmaceutical preparation for the treatment of patients suffering from PD comprising a composition of L-Dopamide
A water-soluble compound could be applied f for rescue therapy. An advantage over the insoluble L-DOPA
Involves an essential structural change to make L-DOPA more soluble and resistant to DOPA Decarboxylase
Administrable without Carbidopa due to resistance to DOPA-decarboxylase
L-Dopamide is slowly hydrolyzed to L-DOPA because it is resistance to DOPA decarboxylase
Slow release addresses the on/off phenomenon of Parkinson’s
Degrades to natural products
Addresses the need for more effective therapy for Parkinson’s disease using a more sustained level of dopamine
Oral application in animal model showed longer duration > 40% over L- DOPA.
Higher efficiency as a proof of concept in experiments made side by side with L-DOPA
PK studies available
Ready for toxicology studies.
VP, Head of Business Development, Healthcare
HUJI, Faculty of Science
The Alexander Silberman Institute for Life Sciences
About Yissum - Research Development Company of the Hebrew University
Technology Transfer Office from IsraelYissum - Research Development Company of the Hebrew University
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.